Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock rose after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
FiercePharma3d
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
MM&M2d
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Daily1d
USFDA approves Bristol Myers Squibb Cobenfy for Schizophrenia treatment in adults
The landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where ...
Business Wire2d
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...